Effect of Intensive Low Sodium Restriction on Glomerular Infiltration Rate in Chronic Kidney Disease
NCT ID: NCT02519894
Last Updated: 2015-08-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
600 participants
INTERVENTIONAL
2015-08-31
2016-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Due to Chronic kidney disease is a public health problem, which is important increased in both developed and developing countries . And sodium intake restriction was related to the reduction of blood pressure and urine protein which is one of the important risk factor in chronic kidney disease. One of the problem in sodium restriction failure in Thai population with CKD nowadays is lack of knowledge and problem unawareness.
The study hypothesis :
Intense knowledge about sodium reduction and immediate feedback of the sodium intake could be simultaneously modifying the behavior to reduce sodium intake , blood pressure and also GFR reduction rate
Objectives :
To compare the effect of dietary salt restriction on glomerular filtration rate (GFR) between CKD patients receiving strict controlled combined with immediate individual feedback (DISC Progrram) and those receiving standard education.
Study design :
Multicenter, open labeled, parallel, randomized controlled trial
Sample size : 600
Primary outcome : GFR reduction (CKD-EPI)
Secondary outcome :
* Achievement rate of Na intake \< 2 g/day (Urine Na \< 90 mEq/day)
* Blood pressure difference
* Proportions of patients with BP reached the target (130/80 mmHg)
* Number of anti-hypertensive drugs use to achieve BP target
* Urine albumin/creatinine ratio
* Major Adverse Cardiac Events (MACE)
* Cardio-ankle vascular index (CAVI)
* ankle-brachial index (ABI)
Documentary Proof of Ethical Clearance :
This project has been reviewed and approved by the Comittee on Human Rights Related to Research Involving Human Subjects , based on the declaration of Helsinki
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
SodiUm Burden Lowered by Lifestyle Intervention: Self-Management and E-health Technology
NCT02132013
Protecting Kidneys Through a Low Protein Diet: A Stepwise Multiple-Choice System Approach
NCT03979534
24-hour Urinary Electrolyte Excretion in Chronic Kidney Disease
NCT05550467
Effectiveness of Integrated Care on Delaying Chronic Kidney Disease Progression in Rural Communities of Thailand
NCT01978951
Simplified Rapid Hydration in Preventing CA-AKI Among Patients With Chronic Kidney Disease
NCT02232997
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
HEALTH_SERVICES_RESEARCH
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Intervention group
Intensive low sodium education and immediate sodium intake feedback by dietary scanning calculator
Dietary Scanning Calculator
Controlled group
Standard education
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dietary Scanning Calculator
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Microalbuminuria
* Any blood pressure level
Exclusion Criteria
* Hyponatremia (Na \< 135 mg/dL) or Hypernatremia (Na \> 145 mg/dL)
* Bilateral renal artery stenosis
* Severe comorbid disease or life expectancy \<1 year (severe cardiovascular disease, chronic liver disease, severe infection , malignancy)
* Immunosuppressant used
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
PANTHITA SORNHIRAN
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
PANTHITA SORNHIRAN
PANTHITA SORNHIRAN
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Ramathibodi Hospital
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.